Skip to main content

How can the industrial world help to implement new vaccines against poverty-related diseases?

  • Chapter

Part of the book series: Birkhäuser Advances in Infectious Diseases BAID ((BAID))

This is a preview of subscription content, log in via an institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. The World Health Organization Model List of Essential Medicines (revised April 2003), available on: www.who.int/medicines/rationale

    Google Scholar 

  2. WHO (1999) Removing obstacles to healthy development: World Health Organization report on infectious disease

    Google Scholar 

  3. Steinbrook R (2004) The AIDS Epidemic in 2004. N Engl J Med 351: 2

    Google Scholar 

  4. WHO Fact Sheet No104 (Revised March 2004) “Basic Facts on TB”

    Google Scholar 

  5. Communication from the European Commission to the Council and the European Parliament (2001) Programme for Action: Accelerated action on HIV/AIDS, malaria and tuberculosis in the context of poverty reduction. COM 96.

    Google Scholar 

  6. DiMasi J, Hansen RW, Grabowski HG (2003) The price of innovation: new estimates of drug development costs. J Health Econ 22: 151–185

    Article  PubMed  Google Scholar 

  7. Global Alliance for TB drug development (2001) The Economics of TB Drug Development. New York

    Google Scholar 

  8. Estimate by the Initiative for Public Private Partnerships for Health (IPPPH): www.ippph.org

    Google Scholar 

  9. US Food and Drug Administration, Office of Orphan Products Development. www.fda.gov/orphan/

    Google Scholar 

  10. Regulation (EC) No 726/2004 of the European Parliament and of the Council (31 March 2004), Article 58, OJ L 136, 30.4.2004, p. 1

    Google Scholar 

  11. Kremer M, Glennerster R (2004) Strong medicine: Creating incentives for Pharmaceutical Research on Neglected Diseases. Princeton University Press, pp 86–96

    Google Scholar 

  12. Klausner RD, Fauci AS, Corey L, Nabel GJ, Gayle H, Berkley S, Haynes BF, Baltimore D, Collins C, Douglas RG et al (2003) The need for a global HIV vaccine enterprise. Science 300: 2036–2039

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Birkhäuser Verlag Basel/Switzerland

About this chapter

Cite this chapter

Olesen, O.F., Hoeveler, A. (2005). How can the industrial world help to implement new vaccines against poverty-related diseases?. In: Kaufmann, S.H., Lambert, PH. (eds) The Grand Challenge for the Future. Birkhäuser Advances in Infectious Diseases BAID. Birkhäuser Basel. https://doi.org/10.1007/3-7643-7381-4_3

Download citation

  • DOI: https://doi.org/10.1007/3-7643-7381-4_3

  • Publisher Name: Birkhäuser Basel

  • Print ISBN: 978-3-7643-7175-3

  • Online ISBN: 978-3-7643-7381-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics